These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Progress of gynecologic oncology in China]. Cao ZY Zhonghua Fu Chan Ke Za Zhi; 1993 Aug; 28(8):463-6. PubMed ID: 8293687 [No Abstract] [Full Text] [Related]
4. [Experiences with the cancer marker CA 125 in gynecologic diseases]. Pilgrim G; von Broen B; Johannsmeyer KD Z Gesamte Inn Med; 1989 Apr; 44(8):251-4. PubMed ID: 2741520 [TBL] [Abstract][Full Text] [Related]
5. Screening for gynecologic malignancies: A continuing responsibility. Runowicz CD; Fields AL Surg Oncol Clin N Am; 1999 Oct; 8(4):703-23, vii. PubMed ID: 10452936 [TBL] [Abstract][Full Text] [Related]
6. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. Miura N; Kanamori Y; Takahashi M; Sato R; Tsukamoto T; Takahashi S; Harada T; Sano A; Shomori K; Harada T; Kigawa J; Ito H; Terakawa N; Hasegawa J; Shiota G Oncol Rep; 2007 Mar; 17(3):541-8. PubMed ID: 17273731 [TBL] [Abstract][Full Text] [Related]
7. [Plasma tumor markers]. Auclerc G; Rixe O; Weil M; Khayat D Contracept Fertil Sex; 1994 Jan; 22(1):23-5. PubMed ID: 8136882 [No Abstract] [Full Text] [Related]
8. [Tumor markers in gynecological and breast cancer]. Jobo T; Sato R; Kuramoto H Rinsho Byori; 2003 Dec; 51(12):1188-94. PubMed ID: 14743742 [TBL] [Abstract][Full Text] [Related]
9. [Comparative immunoenzyme analysis of the fertility alpha2-microglobulin in healthy donors and in patients with gynecological malignancies]. Shcherbakova LA; Tatarinov IuS; Kalashnikov VV; Murashov VA; Olefirenko GO Vopr Med Khim; 1988; 34(5):23-5. PubMed ID: 2464236 [TBL] [Abstract][Full Text] [Related]
11. [Diagnostic significance of tumor markers for gynecologic malignancies]. Aoki D; Hirasawa A; Susumu N Gan To Kagaku Ryoho; 2005 Mar; 32(3):411-6. PubMed ID: 15791829 [TBL] [Abstract][Full Text] [Related]
12. [Screening for malignant gynecologic tumors]. Ebeling K Z Arztl Fortbild (Jena); 1993 Sep; 87(9):715-9. PubMed ID: 8237067 [No Abstract] [Full Text] [Related]
13. Knowledge of tumor markers and the psychological consequences of tumor marker sampling in patients with gynecologic cancers. Mayerhofer K; Bodner K; Aktas C; Schindl M; Kaider A; Leodolter S; Joura EA; Kainz C Anticancer Res; 2000; 20(2B):1281-4. PubMed ID: 10810435 [TBL] [Abstract][Full Text] [Related]
14. [Possibilities and evaluation of the use of tumor markers in gynecologic oncology. 1. Biochemical parameters]. Elling D; Bartel U; Götze W Zentralbl Gynakol; 1987; 109(16):994-1004. PubMed ID: 3673328 [TBL] [Abstract][Full Text] [Related]
15. [Biomarker in gynecologic malignancies]. Isonishi S Gan To Kagaku Ryoho; 2004 Jul; 31(7):1003-7. PubMed ID: 15272576 [TBL] [Abstract][Full Text] [Related]
16. [On a mass screening survey for gynecologic carcinomata in a rural community]. Montanari GR; Grismondi GL; Marconato A; Gioia E; Montanari GD Attual Ostet Ginecol; 1968; 14(5):413-5. PubMed ID: 5737605 [No Abstract] [Full Text] [Related]
17. [Progress in the study of the uses of proteomics in gynecologic oncology]. Yang YS; Chen JL; Wan XP Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):425-7. PubMed ID: 15312333 [No Abstract] [Full Text] [Related]
18. [Our responsibility in the field of gynecologic cancer]. Dolhay B; Jakubecz S; Papp Z; Herpay G; Gardó S Orv Hetil; 1968 Dec; 109(5):2821-5. PubMed ID: 5717809 [No Abstract] [Full Text] [Related]
19. [Mass screening of the uterine cervix in the program of the "Decade of Health": perspectives of gynecologic cancer screening in Hungary]. Országos Tisztifóorvosi Hivatal Méhnyakszúrési Munkacsoport Orv Hetil; 2004 Jan; 145(1):35-40. PubMed ID: 15222140 [No Abstract] [Full Text] [Related]